Orris

this is the paper i am presenting at a conference this will be followed by questions by the judges... prepare me for the same

Reading File
Reading File
Searching the Web

CUTICON conference dermatology India abstract presentation judging criteria

Reading File
Reading File
Browsing Directory

~/

Browsing Directory

~/attachments/180cec6e-51af-4a36-be76-42c8ed21bcdc

Running Command

mkdir -p "/tmp/workspace/conference-qa/src" "/tmp/workspace/conference-qa/output" && python - <<'PY' from pptx import Presentation from pathlib import Path p=Path('/tmp/workspace/attachments/180cec6e-51af-4a36-be76-42c8ed21bcdc/cuticon paper-26 itee [Autosaved].pptx') prs=Presentation(p) out=Path('/tmp/workspace/conference-qa/output/extracted_slides.txt') with out.open('w',encoding='utf-8') as f: f.write(f'Slides: {len(prs.slides)}\n\n') for i,slide in enumerate(prs.slides,1): f.write(f'===== SLIDE {i} =====\n') for shape in slide.shapes: if hasattr(shape,'text') and shape.text.strip(): f.write(shape.text.strip()+'\n') notes=slide.notes_slide if notes and notes.notes_text_frame and notes.notes_text_frame.text.strip(): f.write('NOTES: '+notes.notes_text_frame.text.strip()+'\n') f.write('\n') print(out) PY python /tmp/skills/pptx/scripts/render_slides.py "/tmp/workspace/attachments/180cec6e-51af-4a36-be76-42c8ed21bcdc/cuticon paper-26 itee [Autosaved].pptx" --output_dir "/tmp/workspace/conference-qa/output/rendered"

Reading File
Reading File
Searching PubMed

vitiligo topical tofacitinib tacrolimus

Finding Sources
Finding Sources
Reading File
Running Command

python - <<'PY' from pptx import Presentation from pathlib import Path p='/tmp/workspace/attachments/180cec6e-51af-4a36-be76-42c8ed21bcdc/cuticon paper-26 itee [Autosaved].pptx' prs=Presentation(p) out=Path('/tmp/workspace/conference-qa/output/shape_inventory.txt') with out.open('w',encoding='utf8') as f: for n,s in enumerate(prs.slides,1): f.write(f'\n=====SLIDE {n}=====\n') for i,sh in enumerate(s.shapes): f.write(f'[{i}] type={sh.shape_type} name={sh.name} x={sh.left} y={sh.top} w={sh.width} h={sh.height}\n') if sh.has_table: for row in sh.table.rows: f.write(' | '.join(cell.text.replace('\n',' / ') for cell in row.cells)+'\n') if sh.has_chart: c=sh.chart f.write('chart='+str(c.chart_type)+' categories='+str([x.label for x in c.plots[0].categories])+'\n') for ser in c.series: f.write(f' series={ser.name}: {[v for v in ser.values]}\n') PY unzip -l "/tmp/workspace/attachments/180cec6e-51af-4a36-be76-42c8ed21bcdc/cuticon paper-26 itee [Autosaved].pptx" | sed -n '1,100p'

Reading File
Running Command

python - <<'PY' from pptx import Presentation p='/tmp/workspace/attachments/180cec6e-51af-4a36-be76-42c8ed21bcdc/cuticon paper-26 itee [Autosaved].pptx' prs=Presentation(p) for si in [7,8,9,10,11,12]: s=prs.slides[si-1] print('\n===== SLIDE',si,'=====') for sh in s.shapes: if sh.has_table: for row in sh.table.rows: print(' | '.join(cell.text.replace('\n',' / ') for cell in row.cells)) if sh.has_chart: c=sh.chart for ser in c.series: print('CHART',ser.name, list(ser.values)) PY

Reading File
Searching PubMed

vitiligo tofacitinib topical

Searching the Web

vitiligo treatment guideline topical tacrolimus topical tofacitinib off label 2025

Reading Article

PMID: 40758816

Reading Article

PMID: 38477910

Reading File
Reading File

Your one-line take-home message

“In stable, localized non-segmental vitiligo, topical tofacitinib 2% showed an earlier repigmentation signal than tacrolimus 0.1% over 16 weeks, but this small open-label study is hypothesis-generating and cannot establish superiority.”
Use this wording rather than saying “tofacitinib is superior.”
Your finding aligns with a 2025 randomized intraindividual trial: tofacitinib had a numerically earlier response and fewer adverse events, but the efficacy difference versus tacrolimus was not statistically significant. See the 2025 comparative trial.

Questions judges are most likely to ask

1. “Why did you choose tacrolimus as the comparator?”

Answer: “Tacrolimus 0.1% is a commonly used steroid-sparing topical immunomodulator in localized vitiligo, particularly at facial and intertriginous sites. It is therefore a clinically relevant standard comparator. Tofacitinib acts through a different pathway, JAK inhibition, making this a comparison of established topical immunomodulation with a targeted pathway-directed therapy.”
If they ask for evidence:
“Tacrolimus has good evidence in facial vitiligo. A small randomized study reported at least 75% repigmentation in 65% of adults using tacrolimus 0.1% twice daily for 24 weeks, although responses at non-facial sites are lower.”
  • Dermatology 2-Volume Set, 5e, p. 1312.

2. “Why tofacitinib? Why not topical ruxolitinib?”

Answer: “The rationale for tofacitinib is the central role of IFN-gamma signaling through the JAK-STAT pathway in vitiligo. Tofacitinib is a JAK inhibitor and was selected as an accessible, emerging topical JAK inhibitor for comparison. However, I acknowledge that topical tofacitinib for vitiligo is off-label and less extensively studied than ruxolitinib.”
“Topical ruxolitinib has stronger trial evidence and is FDA-approved in the US for non-segmental vitiligo involving up to 10% BSA in patients aged 12 years or above. Therefore, our findings should not be extrapolated to mean that tofacitinib should replace approved ruxolitinib.”
  • Dermatology 2-Volume Set, 5e, p. 1312.

3. “Explain the mechanism of tofacitinib in vitiligo.”

Answer: “Vitiligo involves autoreactive CD8-positive T cells. IFN-gamma signaling activates JAK-STAT pathways and stimulates chemokines such as CXCL9 and CXCL10, which recruit and retain cytotoxic T cells in the skin. By inhibiting JAK signaling, tofacitinib may interrupt this inflammatory loop, reduce melanocyte-directed immune injury, and allow melanocyte recovery or migration from perifollicular reservoirs.”
Short version:
“Tacrolimus broadly reduces T-cell activation through calcineurin inhibition; tofacitinib more directly targets cytokine signaling central to the IFN-gamma-CXCL10 axis.”

4. “Your sample is only 20 patients. Can you claim superiority?”

Best answer: “No. With 10 patients per arm, the study is underpowered for a definitive superiority claim. I interpret the results as an early efficacy signal and evidence of feasibility, not conclusive proof. A larger, blinded, adequately powered randomized controlled trial is needed.”
This answer will score points. Do not become defensive.

5. “Were your results statistically significant? Where are the p-values and confidence intervals?”

This is the question you must be ready for.
If formal statistical testing was not performed: “This was an exploratory pilot study with a very small sample size. We focused on descriptive trends in physician assessment, VNS, time to visible response, site-wise response, and adverse events. I agree that inferential testing, effect sizes, and confidence intervals would strengthen the analysis and are essential in a future adequately powered trial.”
If testing was performed but omitted from the slides:
Have the exact test, p-value, and effect estimate memorized. Add them to your presentation if possible.
Do not say: “The graph clearly proves it.”
It does not. The observed numerical difference may reflect chance, especially with n=10 per group.

6. “Why did you use an open-label design?”

Answer: “This was a pragmatic pilot study. The formulations and practical dispensing conditions made patient blinding difficult. We attempted to reduce subjectivity by standardized serial photography and predefined clinical assessments. Nevertheless, open-label design can introduce expectation and observer bias, especially for subjective outcomes such as physician-assessed repigmentation and VNS. Blinded outcome assessment would be preferable in future work.”

7. “How was randomization done? What exactly was allocation concealment?”

Your slide says “randomized 1:1” and “allocation concealment,” but it does not state the method. Judges may probe.
Answer only using what actually happened. Prepare this exact sentence with your supervisor: “Randomization was performed using [computer-generated random sequence / random-number table / lottery method], in a 1:1 ratio. Allocation was concealed using [sequentially numbered opaque sealed envelopes / central allocation / other actual method].”
If envelopes were not used, do not claim that they were.
Important: If the method is not clearly documented, remove “allocation concealment” from the slide or replace it with the accurate process. A vague claim invites criticism.

8. “Why include only stable disease?”

Answer: “We wanted to evaluate repigmentation rather than the separate issue of controlling active disease. In active vitiligo, new lesions and extension of older lesions can confound assessment of topical repigmentation. Stable disease gives a more interpretable comparison of treatment-related pigment recovery.”

9. “Why did you choose a 16-week duration?”

Answer: “This was selected as an early-response pilot timeframe, with visits at weeks 4, 8, 12, and 16. However, 16 weeks is short for vitiligo, and that is a key limitation. Standard clinical assessment often requires at least 6 months to assess a treatment adequately. The slower continued improvement seen with tacrolimus at week 16 may reflect that longer treatment is needed for its full effect.”
  • Dermatology 2-Volume Set, 5e, p. 1312.
This directly supports your observation that tacrolimus had not plateaued.

10. “Why did tofacitinib plateau after week 8 while tacrolimus continued to improve?”

Answer: “This is an observation, not a proven biological difference. Possible explanations include early suppression of inflammatory signaling with tofacitinib followed by a slower melanocyte-repopulation phase, lesion-site effects, small-sample variability, adherence variation, or the short follow-up. The continued tacrolimus improvement also suggests that 16 weeks may underestimate its eventual response. This requires confirmation in a larger, longer study.”

11. “Why did sun-exposed lesions respond better?”

Answer: “Sun exposure may provide a natural phototherapeutic effect by stimulating melanocyte activity and repigmentation. Facial and neck lesions also generally respond better to vitiligo treatment, likely because they have a richer follicular melanocyte reservoir. However, sun exposure was not standardized or measured in our study, so this is an association rather than proof of causation.”
  • Dermatology 2-Volume Set, 5e, p. 1312.

12. “Did you advise sunlight exposure? Could it be a confounder?”

Answer: “Natural sunlight exposure was not quantified or standardized. Therefore, it is a potential confounder, particularly for the site-wise findings. We did not interpret sun-exposed-site response as a drug effect alone. Future studies should document sun exposure and ideally standardize phototherapy or stratify by lesion site.”
This is a strong answer.

13. “Why no NB-UVB? JAK inhibitors may need light exposure for repigmentation.”

Answer: “We deliberately evaluated topical monotherapy to isolate the comparative topical effect. However, I agree that NB-UVB is highly relevant because repigmentation often requires both immune control and melanocyte stimulation. The sun-exposed pattern in our results supports evaluating each agent with standardized NB-UVB in future studies.”
For generalized vitiligo, NB-UVB is a first-line treatment approach, especially with greater body-surface-area involvement.
  • Dermatology 2-Volume Set, 5e, p. 1312.

14. “What does ‘no adverse effects’ mean in a sample of 20?”

Answer: “It means that no clinically reported or observed adverse events occurred during this 16-week study in these 20 participants. It does not establish long-term safety or prove absence of adverse effects. The sample and follow-up were insufficient to detect uncommon, delayed, or systemic adverse events.”
Say this exactly. It is scientifically mature.

15. “Did you do laboratory monitoring for topical tofacitinib?”

Use the version that is true for your protocol:
If no routine labs were done: “No routine laboratory monitoring was performed because this was topical use over limited BSA, up to 10%, with short follow-up. However, I acknowledge that systemic absorption and long-term safety were not formally assessed. Future studies should include a predefined safety-monitoring strategy, particularly in children, larger BSA exposure, occluded areas, or prolonged treatment.”
If labs were done:
State precisely which ones, baseline values, follow-up timing, and any abnormal result.

16. “Is topical tofacitinib safe in children, especially your 6-year-old participant?”

Answer: “The study’s pediatric experience is limited, and topical tofacitinib for vitiligo is off-label. Our finding of no adverse events over 16 weeks is reassuring only within this small cohort. It should not be interpreted as establishing pediatric long-term safety. We used limited BSA and clinical surveillance, but larger pediatric safety studies are needed.”
Current pediatric guidance supports topical calcineurin inhibitors and selected topical JAK inhibitors, but the evidence base for topical tofacitinib specifically remains limited. See the 2024 pediatric recommendations.

17. “Why did you include patients above 5 years, but use tacrolimus 0.1%?”

Answer: “Tacrolimus was used as a topical steroid-sparing agent under the study protocol. However, age-specific labeling and local regulatory status must be respected. This is another reason why the findings should be considered exploratory, especially in the pediatric subgroup.”
Do not overstate pediatric safety. Be ready to state your institutional protocol and ethics approval basis.

18. “Why did you switch nonresponders at week 12? Does that not bias week-16 results?”

This is another high-risk question.
Answer: “Yes, switching poor/nonresponders at week 12 complicates interpretation of outcomes at week 16 because post-switch responses may no longer represent the originally allocated treatment. The cleanest analysis is to report the pre-switch outcomes through week 12 as the primary comparative result, and treat post-switch outcomes as exploratory or separately analyze them according to the treatment actually received.”
You should clarify this in the deck.
The audience must know whether week-16 results are based on:
  1. Original assigned treatment only,
  2. Intention-to-treat analysis, or
  3. Participants after switching.
If you cannot explain that clearly, a judge can challenge your conclusion.

Presentation corrections to make before the conference

1. Correct the conclusion language

Current wording to avoid

“Tofacitinib matched or exceeded tacrolimus at every visit.”

Safer replacement

“Topical tofacitinib 2% demonstrated a numerically earlier repigmentation response than topical tacrolimus 0.1% during 16 weeks of follow-up. Given the small open-label sample and short duration, this finding should be considered hypothesis-generating rather than proof of superiority.”

2. Reconcile the sun-exposed numbers

Your slides and notes contain different figures:
  • Slide 11 notes: week 4, 70% vs 30%; week 16, 87.5% vs 62.5%
  • Slide 18: week 4, 78% vs 38%
  • Baseline table: 4 sun-exposed-only patients in each arm, plus 3 versus 4 with both-site disease
These denominators must be reconciled before presenting. A judge may calculate that 87.5% implies 7/8, which does not clearly match the group distribution shown.
Use a table with explicit numerators and denominators, for example:
TimeTofacitinibTacrolimusDenominator definition
Week 4x/yx/yPatients with sun-exposed lesions
Week 16x/yx/yPatients with sun-exposed lesions

3. Define every outcome instrument

Prepare one sentence each:
  • PGA / physician-assessed repigmentation: exact scale, range, anchors, and who performed it.
  • VNS: scale from 1 to 5 and what scores mean.
  • VDAS: which version and how it was used.
  • BSA: method used, such as palm method, rule of nines, or digital assessment.
  • Complete repigmentation: whether it was 100% clinical repigmentation, confirmed from photographs, or another definition.
A judge may ask, “What does a change from 1 to 3.6 in physician score mean clinically?” You need a direct answer.

4. Add statistics, if possible

At minimum, display:
  • n analyzed per arm at each visit
  • number who switched at week 12
  • mean or median change from baseline
  • standard deviation or interquartile range
  • between-group effect estimate
  • p-value and 95% confidence interval, if a valid analysis was done
  • protocol-defined primary endpoint
If no formal analysis was planned, label this explicitly as a pilot exploratory comparative study.

5. Add ethics and trial-registration information

Be ready with:
  • Institutional Ethics Committee approval number
  • Date of approval
  • Written informed consent process
  • Assent process for children, if applicable
  • Whether trial registration was done, and registry number
  • Source of medication and funding
  • Declaration of conflicts of interest

Limitations: say them before a judge does

Use this 20-second statement:
“The main limitations are the small sample size, single-centre open-label design, short 16-week follow-up, absence of standardized UV exposure, possible baseline imbalance in disease duration and lesion sites, subjective outcome assessment, and treatment switching at week 12. Therefore, our results indicate an earlier response signal with topical tofacitinib, not definitive comparative superiority.”

A likely “hostile” question and ideal response

Judge:

“Your study is too small, open-label, does not show p-values, and switches patients at 12 weeks. Why should we believe the conclusion?”

You:

“Those are valid limitations. Our study should not be viewed as definitive efficacy evidence. Its contribution is a prospective head-to-head pilot comparison in stable localized non-segmental vitiligo, showing an early numerical response signal with topical tofacitinib and no observed short-term adverse effects. The study helps define the design for a larger blinded trial with standardized photography, VASI-based outcomes, predefined statistics, longer follow-up, and no cross-over before the primary endpoint.”
That response changes a weakness into a credible future-research plan.

Final 30-second closing answer

“Our study suggests that topical tofacitinib 2% may produce earlier visible repigmentation than tacrolimus 0.1% in stable localized non-segmental vitiligo. Both agents improved disease over 16 weeks and were well tolerated in this small cohort. Because the study was open-label, single-centre, and included only 20 patients, we interpret the finding as a promising early signal. Larger blinded trials with longer follow-up, standardized light exposure, validated VASI outcomes, and robust safety monitoring are needed before changing routine practice.”
The most important adjustment is this: be confident about your observation, but conservative about what it proves.
This is a shared conversation. Sign in to Orris to start your own chat.